In NSCLC, this bifunctional PD-L1 and TGF-β inhibitor prevented tumor endogenous mesenchalization compared with PD-L1 inhibition alone and enhance antibody-dependent cellular cytotoxicity (ADCC) in cervical, breast, and prostate cancer cell lines (40, 41). The gene discussed is CD274; the disease is prostate cancer.